MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 264 filers reported holding MYRIAD GENETICS INC in Q1 2019. The put-call ratio across all filers is 2.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,283 | -23.8% | 142,372 | +10.1% | 0.00% | -50.0% |
| Q2 2023 | $2,997 | +23.5% | 129,304 | +23.7% | 0.00% | +100.0% |
| Q1 2023 | $2,427 | +18.2% | 104,510 | -26.1% | 0.00% | 0.0% |
| Q4 2022 | $2,053 | -99.9% | 141,447 | +5.4% | 0.00% | -66.7% |
| Q3 2022 | $2,561,000 | +315.1% | 134,244 | +295.4% | 0.00% | – |
| Q2 2022 | $617,000 | -65.5% | 33,953 | -52.2% | 0.00% | -100.0% |
| Q1 2022 | $1,790,000 | -71.5% | 71,015 | -68.8% | 0.00% | 0.0% |
| Q4 2021 | $6,278,000 | +89.8% | 227,426 | +122.0% | 0.00% | 0.0% |
| Q3 2021 | $3,308,000 | +134.9% | 102,424 | +122.4% | 0.00% | 0.0% |
| Q2 2021 | $1,408,000 | -50.5% | 46,048 | -50.7% | 0.00% | -50.0% |
| Q1 2021 | $2,846,000 | +67.0% | 93,485 | +8.5% | 0.00% | +100.0% |
| Q4 2020 | $1,704,000 | -15.5% | 86,190 | -44.2% | 0.00% | 0.0% |
| Q3 2020 | $2,016,000 | +149.8% | 154,591 | +117.3% | 0.00% | 0.0% |
| Q2 2020 | $807,000 | -73.1% | 71,149 | -66.0% | 0.00% | -50.0% |
| Q1 2020 | $2,996,000 | -74.0% | 209,297 | -50.6% | 0.00% | -66.7% |
| Q4 2019 | $11,531,000 | +299.7% | 423,447 | +320.1% | 0.01% | +500.0% |
| Q3 2019 | $2,885,000 | -67.1% | 100,794 | -68.1% | 0.00% | -80.0% |
| Q2 2019 | $8,774,000 | +85.3% | 315,855 | +121.4% | 0.01% | +66.7% |
| Q1 2019 | $4,735,000 | +379.3% | 142,646 | +319.6% | 0.00% | +200.0% |
| Q4 2018 | $988,000 | -78.9% | 33,993 | -66.6% | 0.00% | -66.7% |
| Q3 2018 | $4,684,000 | +153.5% | 101,841 | +105.8% | 0.00% | +200.0% |
| Q2 2018 | $1,848,000 | -62.9% | 49,481 | -70.7% | 0.00% | -75.0% |
| Q1 2018 | $4,983,000 | +116.7% | 168,608 | +151.9% | 0.00% | +100.0% |
| Q4 2017 | $2,299,000 | -40.4% | 66,940 | -37.2% | 0.00% | -33.3% |
| Q3 2017 | $3,858,000 | +10.4% | 106,607 | -21.1% | 0.00% | 0.0% |
| Q2 2017 | $3,494,000 | +68.2% | 135,183 | +25.0% | 0.00% | +50.0% |
| Q1 2017 | $2,077,000 | -7.7% | 108,179 | -19.8% | 0.00% | 0.0% |
| Q4 2016 | $2,250,000 | -8.9% | 134,957 | +12.4% | 0.00% | 0.0% |
| Q3 2016 | $2,471,000 | +319.5% | 120,084 | +524.7% | 0.00% | +100.0% |
| Q2 2016 | $589,000 | -52.0% | 19,223 | -42.0% | 0.00% | 0.0% |
| Q1 2016 | $1,227,000 | -19.5% | 33,152 | -6.4% | 0.00% | -50.0% |
| Q4 2015 | $1,524,000 | -82.0% | 35,417 | -84.5% | 0.00% | -80.0% |
| Q3 2015 | $8,447,000 | +62.4% | 228,262 | +44.8% | 0.01% | +66.7% |
| Q2 2015 | $5,201,000 | -51.9% | 157,610 | -49.0% | 0.01% | -50.0% |
| Q1 2015 | $10,815,000 | +84.8% | 309,021 | +79.5% | 0.01% | +100.0% |
| Q4 2014 | $5,852,000 | -19.8% | 172,120 | -10.4% | 0.01% | -14.3% |
| Q3 2014 | $7,300,000 | -16.0% | 192,079 | -16.0% | 0.01% | -22.2% |
| Q2 2014 | $8,693,000 | -18.2% | 228,776 | -26.8% | 0.01% | -25.0% |
| Q1 2014 | $10,625,000 | -32.1% | 312,466 | -60.0% | 0.01% | -25.0% |
| Q4 2013 | $15,643,000 | +74.5% | 782,119 | +100.6% | 0.02% | +60.0% |
| Q3 2013 | $8,966,000 | -39.7% | 389,831 | -29.6% | 0.01% | -47.4% |
| Q2 2013 | $14,874,000 | – | 553,548 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |